These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 25394038)

  • 1. HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis.
    Brinson C; Lalezari J; Gulam LH; Thompson M; Echevarria J; Treviño-Pérez S; Stock D; Samit JR; George HJ; Lataillade M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19529. PubMed ID: 25394038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis.
    Lalezari J; Latiff GH; Brinson C; Echevarria J; Treviño-Pérez S; Bogner JR; Stock D; Joshi SR; Hanna GJ; Lataillade M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19530. PubMed ID: 25394039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
    Thompson M; Lalezari JP; Kaplan R; Pinedo Y; Pena OAS; Cahn P; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
    Antivir Ther; 2017; 22(3):215-223. PubMed ID: 27922453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
    Lalezari JP; Latiff GH; Brinson C; Echevarría J; Treviño-Pérez S; Bogner JR; Thompson M; Fourie J; Sussmann Pena OA; Mendo Urbina FC; Martins M; Diaconescu IG; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
    Lancet HIV; 2015 Oct; 2(10):e427-37. PubMed ID: 26423650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
    Zhu L; Hruska M; Hwang C; Shah V; Furlong M; Hanna GJ; Bertz R; Landry IS
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3816-22. PubMed ID: 25870057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
    Elion R; Cohen C; Gathe J; Shalit P; Hawkins T; Liu HC; Mathias AA; Chuck SL; Kearney BP; Warren DR;
    AIDS; 2011 Sep; 25(15):1881-6. PubMed ID: 21811136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
    Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
    Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
    Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
    Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
    AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
    Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.
    Squires KE; Young B; Santiago L; Dretler RH; Walmsley SL; Zhao HH; Pakes GE; Ross LL; Shaefer MS
    HIV AIDS (Auckl); 2017; 9():51-61. PubMed ID: 28424561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
    Jarrin I; Hernández-Novoa B; Alejos B; Santos I; Lopez-Aldeguer J; Riera M; Gutiérrez F; Rubio R; Antela A; Blanco JR; Moreno S;
    HIV Med; 2014 Oct; 15(9):547-56. PubMed ID: 24655804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala.
    Laker E; Mambule I; Nalwanga D; Musaazi J; Kiragga A; Parkes-Ratanshi R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19792. PubMed ID: 25397536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults.
    Arathoon E; Bhorat A; Silaghi R; Crauwels H; Lavreys L; Tambuyzer L; Vanveggel S; Opsomer M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19783. PubMed ID: 25397527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression.
    Carbone A; Galli L; Bigoloni A; Bossolasco S; Guffanti M; Maillard M; Carini E; Salpietro S; Spagnuolo V; Gianotti N; Lazzarin A; Castagna A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19811. PubMed ID: 25397555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.
    Fabbiani M; Di Giambenedetto S; Quiros-Roldan E; Latini A; Vullo V; Antinori A; Castagna A; Orofino G; Francisci D; Grilli E; Madeddu G; Grima P; Rusconi S; Del Pin B; Mondi A; Borghetti A; Focà E; Colafigli M; De Luca A; Cauda R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19808. PubMed ID: 25397552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.